Fluidigm plots $86M IPO; Medivir raises $41M for PhIII; Biocon readies cancer vax for trial;

 @FierceBiotech: Enzon axes 33 staffers as it tries to rein in costs. Report | Follow @FierceBiotech

> Fluidigm, which makes tools for genetic analysis, plans to raise $86 million in an IPO. The South San Francisco company is a supplier to the life sciences industry. Story

> Medivir AB has raised $41 million from a private placement, clearing the path for a Phase III study of its hep C therapy, TMC435. Report

> India's Biocon has laid plans to launch human trials of a new cancer vaccine in 2011. Biocon is partnered with IATRICa Inc. on the deal. Report

> Immune Pharmaceuticals is paying $1 million to gain an option on an exclusive license for Co-008, iCo's human monoclonal antibody targeting eotaxin-1. iCo may receive up to an additional $32 million in milestone payments as well as royalties on net sales of licensed products. iCo release

And Finally... When an antibiotic is consumed, researchers have learned that up to 90 percent passes through a body without metabolizing. This means the drugs can leave the body almost intact through normal bodily functions. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.